These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 36448189)

  • 1. Efficacy and safety of brolucizumab for serous drusenoid pigment epithelium detachment non-responder to bevacizumab and aflibercept.
    Saitta A; D'Eliseo LA; D'Eliseo D
    Eur J Ophthalmol; 2023 Nov; 33(6):NP109-NP112. PubMed ID: 36448189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.
    Clemens CR; Alten F; Termühlen J; Mihailovic N; Rosenberger F; Heiduschka P; Eter N
    Graefes Arch Clin Exp Ophthalmol; 2020 Jul; 258(7):1411-1417. PubMed ID: 32306096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brolucizumab for pre-treated patients with choroidal neovascularization and signs of tachyphylaxis to aflibercept and bevacizumab.
    Boltz A; Radunsky K; Weingessel B; Vécsei-Marlovits VP
    Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2561-2566. PubMed ID: 35348844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
    Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
    BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab simultaneous combined with dexamethasone implant for treatment of neovascular serous retinal pigment epithelial detachment secondary to neovascular age-related macular degeneration.
    Limon U; Sezgin Akcay BI
    Eur J Ophthalmol; 2022 Sep; 32(5):NP32-NP36. PubMed ID: 33781113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-Life Experience and Predictors of Visual Outcomes with Intravitreal Brolucizumab Switch for Treatment of Neovascular Age-Related Macular Degeneration.
    Cavalleri M; Tombolini B; Sacconi R; Gatta G; Valeri R; Bandello F; Querques G
    Ophthalmologica; 2023; 246(2):158-168. PubMed ID: 37040734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration.
    Abdin AD; Aljundi W; El Jawhari K; Suffo S; Weinstein I; Seitz B
    Front Pharmacol; 2022; 13():860784. PubMed ID: 35721125
    [No Abstract]   [Full Text] [Related]  

  • 8. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
    Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
    J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laser and anti-vascular endothelial growth factor treatment for drusenoid pigment epithelial detachment in age-related macular degeneration.
    Kim MS; Ryoo NK; Park KH
    Sci Rep; 2020 Sep; 10(1):14370. PubMed ID: 32873842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
    Singh RP; Jhaveri C; Wykoff CC; Gale RP; Staurenghi G; Iida T; Koh A; B G; Gedif K; Singer M
    Ophthalmol Retina; 2022 May; 6(5):377-386. PubMed ID: 34968756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OUTCOME OF INTRAVITREAL AFLIBERCEPT FOR REFRACTORY PIGMENT EPITHELIAL DETACHMENT WITH OR WITHOUT SUBRETINAL FLUID AND SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
    Kim K; Kim ES; Kim Y; Yang JH; Yu SY; Kwak HW
    Retina; 2019 Feb; 39(2):303-313. PubMed ID: 29160779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brolucizumab for recalcitrant macular neovascularization in age-related macular degeneration with pigment epithelial detachment.
    Chronopoulos A; Huynh E; Ashurov A; Schutz JS; Jonas JB; Hattenbach LO
    Eur J Ophthalmol; 2024 Mar; 34(2):487-496. PubMed ID: 37461836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration.
    Nguyen QD; Das A; Do DV; Dugel PU; Gomes A; Holz FG; Koh A; Pan CK; Sepah YJ; Patel N; MacLeod H; Maurer P
    Ophthalmology; 2020 Jul; 127(7):963-976. PubMed ID: 32107066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients.
    Mishra SK; Kumar P; Khullar S; Joshi A; Sati A; Kumar SV; Unni D; Kumar A
    Int J Retina Vitreous; 2022 Jul; 8(1):51. PubMed ID: 35902887
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choroidal Effusion following Intravitreal Brolucizumab Injection: A Case Report.
    Sim HE; Kim JS; Hwang JH
    Case Rep Ophthalmol; 2022; 13(1):166-171. PubMed ID: 35611023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventive Inflammation Management with Steroids before Retreatment with Anti-VEGF after Severe Inflammation due to Brolucizumab.
    Karmy BE; Castro DG; Ambresin A
    Klin Monbl Augenheilkd; 2023 Apr; 240(4):556-562. PubMed ID: 37164395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Treat-and-Extend Regimen of Intravitreal Brolucizumab for Exudative Age-Related Macular Degeneration Refractory to Aflibercept: A 12-Month Result.
    Kikushima W; Sakurada Y; Fukuda Y; Matsubara M; Kotoda Y; Sugiyama A; Kashiwagi K
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to brolucizumab treatment for refractory serous pigment epithelial detachment secondary to polypoidal choroidal vasculopathy.
    Nam SW; Byun Z; Ham DI; Kong M
    BMC Ophthalmol; 2022 Dec; 22(1):485. PubMed ID: 36514022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.